Sudbury, MA, United States of America

Janusz Puc

This inventor holds 1 USPTO granted patent. Top assignee: Affyimmune Therapeutics, Inc.. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Janusz Puc: Innovator in Cancer Therapy

Introduction

Janusz Puc is a notable inventor based in Sudbury, MA (US). He has made significant contributions to the field of cancer therapy through his innovative work on EpCAM antibodies and CAR-T cells. His research focuses on developing targeted treatments that can effectively combat cancer while minimizing damage to healthy tissues.

Latest Patents

Janusz Puc holds a patent for his invention titled "EpCAM antibody and CAR-T cells." This patent describes EpCAM antibodies with varying affinities and chimeric antigen receptors (CARs) that are specific to EpCAM. The invention aims to create CAR T cells that can selectively target cancer cells overexpressing EpCAM, thereby avoiding healthy tissues with low EpCAM expression. This approach not only enhances the efficacy of cancer treatment but also promotes long-term patient safety.

Career Highlights

Janusz Puc is currently associated with Affyimmune Therapeutics, Inc., where he continues to advance his research in cancer therapies. His work has the potential to revolutionize the way cancer is treated, offering new hope to patients suffering from this devastating disease.

Collaborations

Janusz collaborates with talented individuals in his field, including Huan Yang and Moonsoo Jin. Their combined expertise contributes to the innovative research and development efforts at Affyimmune Therapeutics, Inc.

Conclusion

Janusz Puc's contributions to cancer therapy through his patent on EpCAM antibodies and CAR-T cells exemplify the impact of innovation in medicine. His work not only addresses critical challenges in cancer treatment but also paves the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…